A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy

J Thorac Oncol. 2019 Sep;14(9):e201-e202. doi: 10.1016/j.jtho.2019.04.013.

Authors

Wenfeng Fang¹, Yihua Huang¹, Jiadi Gan¹, Shaodong Hong¹, Li Zhang²

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
² Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. Electronic address: [email protected].

PMID: 31445736
DOI: 10.1016/j.jtho.2019.04.013

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / administration & dosage
Aniline Compounds / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / enzymology
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Cetuximab / administration & dosage
ErbB Receptors / genetics
ErbB Receptors / metabolism
Exons
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Middle Aged

Substances

Acrylamides
Aniline Compounds
osimertinib
EGFR protein, human
ErbB Receptors
Cetuximab